|
Gene: TSSC4 |
Gene summary for TSSC4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TSSC4 | Gene ID | 10078 |
Gene name | tumor suppressing subtransferable candidate 4 | |
Gene Alias | TSSC4 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q9Y5U2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10078 | TSSC4 | LZE4T | Human | Esophagus | ESCC | 4.29e-06 | 9.18e-02 | 0.0811 |
10078 | TSSC4 | LZE5T | Human | Esophagus | ESCC | 2.38e-02 | 2.05e-01 | 0.0514 |
10078 | TSSC4 | LZE7T | Human | Esophagus | ESCC | 8.83e-04 | 3.46e-01 | 0.0667 |
10078 | TSSC4 | LZE8T | Human | Esophagus | ESCC | 2.66e-11 | 2.36e-01 | 0.067 |
10078 | TSSC4 | LZE20T | Human | Esophagus | ESCC | 3.51e-07 | 9.89e-02 | 0.0662 |
10078 | TSSC4 | LZE22T | Human | Esophagus | ESCC | 4.59e-06 | 2.32e-01 | 0.068 |
10078 | TSSC4 | LZE24T | Human | Esophagus | ESCC | 8.99e-22 | 7.46e-01 | 0.0596 |
10078 | TSSC4 | LZE6T | Human | Esophagus | ESCC | 1.70e-02 | 1.95e-01 | 0.0845 |
10078 | TSSC4 | P1T-E | Human | Esophagus | ESCC | 4.09e-08 | 3.95e-01 | 0.0875 |
10078 | TSSC4 | P2T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.70e-01 | 0.1177 |
10078 | TSSC4 | P4T-E | Human | Esophagus | ESCC | 4.22e-17 | 4.49e-01 | 0.1323 |
10078 | TSSC4 | P5T-E | Human | Esophagus | ESCC | 3.71e-15 | 2.84e-01 | 0.1327 |
10078 | TSSC4 | P8T-E | Human | Esophagus | ESCC | 1.30e-18 | 2.74e-01 | 0.0889 |
10078 | TSSC4 | P9T-E | Human | Esophagus | ESCC | 8.95e-22 | 5.62e-01 | 0.1131 |
10078 | TSSC4 | P10T-E | Human | Esophagus | ESCC | 5.39e-20 | 3.98e-01 | 0.116 |
10078 | TSSC4 | P11T-E | Human | Esophagus | ESCC | 2.02e-18 | 9.12e-01 | 0.1426 |
10078 | TSSC4 | P12T-E | Human | Esophagus | ESCC | 7.19e-32 | 6.18e-01 | 0.1122 |
10078 | TSSC4 | P15T-E | Human | Esophagus | ESCC | 4.80e-23 | 5.55e-01 | 0.1149 |
10078 | TSSC4 | P16T-E | Human | Esophagus | ESCC | 2.26e-29 | 3.59e-01 | 0.1153 |
10078 | TSSC4 | P17T-E | Human | Esophagus | ESCC | 5.77e-14 | 7.34e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TSSC4 | SNV | Missense_Mutation | c.269N>G | p.Ser90Cys | p.S90C | Q9Y5U2 | protein_coding | deleterious(0) | benign(0.189) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
TSSC4 | SNV | Missense_Mutation | novel | c.603N>G | p.Phe201Leu | p.F201L | Q9Y5U2 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TSSC4 | SNV | Missense_Mutation | c.924N>C | p.Arg308Ser | p.R308S | Q9Y5U2 | protein_coding | deleterious(0) | benign(0.165) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TSSC4 | SNV | Missense_Mutation | novel | c.95G>T | p.Ser32Ile | p.S32I | Q9Y5U2 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
TSSC4 | SNV | Missense_Mutation | rs780342193 | c.425G>A | p.Arg142Gln | p.R142Q | Q9Y5U2 | protein_coding | tolerated(0.65) | benign(0) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TSSC4 | SNV | Missense_Mutation | rs778122292 | c.567N>C | p.Gln189His | p.Q189H | Q9Y5U2 | protein_coding | tolerated(0.06) | possibly_damaging(0.466) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
TSSC4 | SNV | Missense_Mutation | c.707G>C | p.Gly236Ala | p.G236A | Q9Y5U2 | protein_coding | tolerated(0.77) | benign(0.115) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TSSC4 | SNV | Missense_Mutation | rs375904217 | c.659N>A | p.Arg220Gln | p.R220Q | Q9Y5U2 | protein_coding | deleterious(0.01) | possibly_damaging(0.794) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
TSSC4 | insertion | Frame_Shift_Ins | novel | c.798_799insG | p.Glu267GlyfsTer3 | p.E267Gfs*3 | Q9Y5U2 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
TSSC4 | insertion | Frame_Shift_Ins | novel | c.799_800insGA | p.Glu267GlyfsTer149 | p.E267Gfs*149 | Q9Y5U2 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |